These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 16423088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
    Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, Seto WK, Wong SY, Chan CK, Gu Q, Tong TS, Cheung TK, Chu KM, Wong BC.
    Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
    Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC.
    J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [Abstract] [Full Text] [Related]

  • 10. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
    Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S.
    J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
    Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, Shang L, Pan XL, Shi RH, Zhang GX.
    Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection.
    Tursi A, Picchio M, Elisei W.
    J Gastrointestin Liver Dis; 2012 Jun; 21(2):133-8. PubMed ID: 22720300
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
    Cheng HC, Chang WL, Chen WY, Yang HB, Wu JJ, Sheu BS.
    Helicobacter; 2007 Aug; 12(4):359-63. PubMed ID: 17669110
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q, Pan Y, Zhang L, Xiao SD.
    Chin J Dig Dis; 2005 Aug; 6(4):202-5. PubMed ID: 16246231
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
    Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH.
    Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
    [Abstract] [Full Text] [Related]

  • 18. Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children.
    Arenz T, Antos D, Rüssmann H, Alberer M, Buderus S, Kappler M, Koletzko S.
    J Pediatr Gastroenterol Nutr; 2006 Aug; 43(2):180-4. PubMed ID: 16877981
    [Abstract] [Full Text] [Related]

  • 19. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.
    Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D.
    Clin Gastroenterol Hepatol; 2013 May; 11(5):507-10. PubMed ID: 23267869
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection.
    Yee YK, Cheung TK, Chu KM, Chan CK, Fung J, Chan P, But D, Hung I, Chan AO, Yuen MF, Hsu A, Wong BC.
    Aliment Pharmacol Ther; 2007 Oct 01; 26(7):1063-7. PubMed ID: 17877513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.